RECIP 1.0 + PSA for response assessment in mCRPC patients treated with 225Ac / 177Lu PSMA combination therapy
ALCT is a promising therapeutic regimen that may prolong survival in patients who progress during [<sup>177</sup>Lu]Lu-PSMA RLT. Our results motivate to further investigate the use of RECIP + PSA as tool for response assessment and for overall survival prediction in mCRPC under ALCT.
Authors
- Lena M. Unterrainer
- Andrei Gafita (ORCID: https://orcid.org/0000-0002-4865-9192)
- Johannes Rübenthaler (ORCID: https://orcid.org/0000-0003-0832-5662)
- Adrien Holzgreve (ORCID: https://orcid.org/0000-0002-9566-8438)
- Gabriel T. Sheikh (ORCID: https://orcid.org/0000-0002-7026-9203)
- Jozefina Casuscelli (ORCID: https://orcid.org/0000-0002-9899-1986)
- Marcus Unterrainer (ORCID: https://orcid.org/0000-0002-8238-1198)
- Astrid Delker
- Mathias J. Zacherl
- Sarah L. Takayama Fouladgar
Institutions
- Johns Hopkins University (US)
- LMU Klinikum (DE)
- Ihre-Radiologen (DE)
- Johns Hopkins Hospital (US)
- Molecular Theranostics (United States) (US)
- Ludwig-Maximilians-Universität München (DE)
Publication Details
- Journal
- EJNMMI Research
- Published
- 2025-03-04
- DOI
- https://doi.org/10.1186/s13550-025-01211-z
- Citations
- 9
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 13.67